WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are ...

There are multiple chapters near you. Select your preferred chapter.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and ...

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Askanase, MD, MPH, shares potential highlights for the upcoming ACR Convergence 2024 and how ... results — one for obinutuzumab in lupus nephritis and another for dapirolizumab in systemic ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

When data from two data sources were analyzed -- one of commercial health insurance claims, the other from Medicare -- ...

We are proud to share data and analyses, including clinical biomarker data, at ACR that support the potential ... refractory class III or class IV lupus nephritis (LN). Adicet is exploring the ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...